Dapoxetine Priligy

What is Priligy: What does Priligy contain?

The history of Priligy dates back to 2004. At that time, dapoxetine was first developed by Ortho-McNeil Pharmaceutical, a subsidiary of Johnson & Johnson, as a drug to treat premature ejaculation in men. Dapoxetine is a selective serotonin reuptake inhibitor (SSRI), which means it is able to inhibit the reuptake of serotonin in the brain, thereby delaying the time of ejaculation. In the following years, dapoxetine underwent a series of clinical trials to evaluate its efficacy and safety for premature ejaculation. These clinical trials involved thousands of male participants with premature ejaculation, and the results showed that dapoxetine had a significant effect in prolonging the time to ejaculation and improving sexual satisfaction.

Based on these trial results, Ortho-McNeil Pharmaceutical obtained marketing authorization for PRILIGY in Europe in 2009. PRILIGY became the first premature ejaculation treatment to receive marketing authorization in Europe.